Trial · NCT04343521
Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases
NCT04343521, Not applicable, Completed, Emory University; results first posted 2025-09-18
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases. Trials, record NCT04343521. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04343521
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases
- NCT number
- NCT04343521
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 4,461 participants, actual
- Lead sponsor
- Emory University
- Conditions
- Aedes-borne Diseases, Dengue, Chikungunya, Zika
- Interventions
- Targeted Indoor Residual Spraying (TIRS)
- First posted
- 2020-04-13
- Last updated
- 2025-09-18
- Results first posted
- 2025-09-18
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Symptomatic Participants Testing Positive for Aedes-borne Virus Infections That Are Laboratory Confirmed or Serologically | 18 months of active surveillance during high transmission seasons (each 6 months in duration) during 3 years (July through December in 2021, 2022, and 2023) | The number of symptomatic children with laboratory confirmed, by reverse transcription-polymerase chain reaction (RT-PCR) or immunoglobulin M/ immunoglobulin G (IgM/IgG) enzyme-linked immunosorbent assay (ELISA), Aedes-borne Viruses infections. The number of any Aedes-borne virus infection during three seasons of high transmission is described, as well as the number of Dengue virus (DENV), Chikungunya virus (CHIKV), Zika virus (ZIKV) and coinfections. |
| Secondary | Number Positive Tests of Laboratory Confirmed Aedes-borne Viruses Infections By Season | Up to 36 months, during serosurvey seasons 2021-2022, 2022-2023, and 2023-2024 | Number of laboratory confirmed (IgG ELISA and neutralization testing) Aedes-borne Viruses (DENV, CHIKV and ZIKV) in annual surveillance samples. |
| Secondary | Ae. Aegypti Mosquito Infection Rate With Aedes-borne Viruses (DENV, CHIKV and ZIKV) | Up to 6 months (mosquito pools were collected during the 6 months post TIRS spraying samplings in 2021) | Ae. aegypti mosquito infection rate with Aedes-borne Viruses (DENV, CHIKV and ZIKV) assessed by the number of positive RT-PCR tests. Infection is mosquitoes is analyzed by collecting binary data (a mosquito pool is either infected or not) and transforming that into minimum infection rates (MIR) with the calculation: (1/number of mosquitoes in the pool) times 1000. Households were randomly selected for testing; houses were eligible for testing if they were located within the central blocks and had at least one child enrolled in the study. |
| Secondary | Ae. Aegypti Indoor Entomological Index of Adult Mosquito Abundance | Up to 36 months starting at the first TIRS application | The Ae. aegypti indoor entomological index of adult mosquito presence/abundance is calculated as the number of adult mosquitoes per house. Higher values mean that more mosquitoes are found within houses. |
| Secondary | Ae. Aegypti Indoor Entomological Index of Female Mosquito Abundance | Up to 36 months starting at first TIRS application | The Ae. aegypti indoor entomological index of female mosquito presence/abundance is calculated as the number of female mosquitoes per house. Higher values mean that more mosquitoes are found within houses. |
| Secondary | Ae. Aegypti Indoor Entomological Index of Bloodfed Female Mosquito Abundance | Up to 36 months starting at first TIRS application | The Ae. aegypti indoor entomological index of bloodfed female mosquito presence/abundance is calculated as the number of bloodfed female mosquitoes per house. Higher values mean that more mosquitoes are found within houses. |
| Secondary | Number of Households Where the Head of Household Would Recommend the Intervention | Post-intervention (up to 41 months and 26 days after the start of the intervention) | Acceptability of the intervention is determined through household surveys, for households that received the intervention. Acceptability is assessed as the number of households where the head of that household would recommend the intervention to others. |
| Secondary | Number of Households With a Resident That Had a Reaction to the Insecticide | Post-intervention (up to 41 months and 26 days after the start of the intervention) | Safety of the intervention is assessed as the number of households receiving the TIRS intervention that had evidence of a household resident having a reaction possibly related to the insecticide, which was assessed and confirmed by study doctors. |
Source ClinicalTrials.gov
Outcomes8
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Symptomatic Participants Testing Positive for Aedes-borne Virus Infections That Are Laboratory Confirmed or Serologically | 18 months of active surveillance during high transmission seasons (each 6 months in duration) during 3 years (July through December in 2021, 2022, and 2023) | This analysis includes symptomatic children who were tested for Andes-borne viruses during high transmission seasons. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number Positive Tests of Laboratory Confirmed Aedes-borne Viruses Infections By Season | Up to 36 months, during serosurvey seasons 2021-2022, 2022-2023, and 2023-2024 | The population analyzed includes children living in study households where annual surveillance sampling for Aedes-borne viruses occurred. | Number of Tests | COUNT_OF_UNITS |
| SECONDARY | Ae. Aegypti Mosquito Infection Rate With Aedes-borne Viruses (DENV, CHIKV and ZIKV) | Up to 6 months (mosquito pools were collected during the 6 months post TIRS spraying samplings in 2021) | This analysis includes households where mosquito sampling occurred. Individual participants were not analyzed. Only households contributed data. | Households samples | COUNT_OF_UNITS |
| SECONDARY | Ae. Aegypti Indoor Entomological Index of Adult Mosquito Abundance | Up to 36 months starting at the first TIRS application | mosquitoes/house | MEAN | |
| SECONDARY | Ae. Aegypti Indoor Entomological Index of Female Mosquito Abundance | Up to 36 months starting at first TIRS application | mosquitoes/house | MEAN | |
| SECONDARY | Ae. Aegypti Indoor Entomological Index of Bloodfed Female Mosquito Abundance | Up to 36 months starting at first TIRS application | mosquitoes/house | MEAN | |
| SECONDARY | Number of Households Where the Head of Household Would Recommend the Intervention | Post-intervention (up to 41 months and 26 days after the start of the intervention) | This analysis includes households in TIRS clusters where the head of the household completed the household survey. | Households | COUNT_OF_UNITS |
| SECONDARY | Number of Households With a Resident That Had a Reaction to the Insecticide | Post-intervention (up to 41 months and 26 days after the start of the intervention) | This analysis includes households in TIRS clusters where the head of the household completed the household survey. | Households | COUNT_OF_UNITS |
Source ClinicalTrials.gov
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Symptomatic Participants Testing Positive for Aedes-borne Virus Infections That Are Laboratory Confirmed or Serologically | Targeted Indoor Residual Spraying (TIRS) | Number of Children Testing Positive for All Aedes-borne Viruses | 213 | Participants | |
| Number of Symptomatic Participants Testing Positive for Aedes-borne Virus Infections That Are Laboratory Confirmed or Serologically | Routine Aedes-borne Virus (ABV) Prevention and Control | Number of Children Testing Positive for All Aedes-borne Viruses | 209 | Participants | |
| Number of Symptomatic Participants Testing Positive for Aedes-borne Virus Infections That Are Laboratory Confirmed or Serologically | Targeted Indoor Residual Spraying (TIRS) | Number of Children Testing Positive for DENV | 151 | Participants | |
| Number of Symptomatic Participants Testing Positive for Aedes-borne Virus Infections That Are Laboratory Confirmed or Serologically | Routine Aedes-borne Virus (ABV) Prevention and Control | Number of Children Testing Positive for DENV | 146 | Participants | |
| Number of Symptomatic Participants Testing Positive for Aedes-borne Virus Infections That Are Laboratory Confirmed or Serologically | Targeted Indoor Residual Spraying (TIRS) | Number of Children Testing Positive for CHIKV | 1 | Participants | |
| Number of Symptomatic Participants Testing Positive for Aedes-borne Virus Infections That Are Laboratory Confirmed or Serologically | Routine Aedes-borne Virus (ABV) Prevention and Control | Number of Children Testing Positive for CHIKV | 0 | Participants | |
| Number of Symptomatic Participants Testing Positive for Aedes-borne Virus Infections That Are Laboratory Confirmed or Serologically | Targeted Indoor Residual Spraying (TIRS) | Number of Children Testing Positive for ZIKV | 39 | Participants | |
| Number of Symptomatic Participants Testing Positive for Aedes-borne Virus Infections That Are Laboratory Confirmed or Serologically | Routine Aedes-borne Virus (ABV) Prevention and Control | Number of Children Testing Positive for ZIKV | 55 | Participants | |
| Number of Symptomatic Participants Testing Positive for Aedes-borne Virus Infections That Are Laboratory Confirmed or Serologically | Targeted Indoor Residual Spraying (TIRS) | Number of Children Testing Positive for Coinfection | 22 | Participants | |
| Number of Symptomatic Participants Testing Positive for Aedes-borne Virus Infections That Are Laboratory Confirmed or Serologically | Routine Aedes-borne Virus (ABV) Prevention and Control | Number of Children Testing Positive for Coinfection | 8 | Participants |
1 to 10 of 26Source ClinicalTrials.gov
See all 26 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Targeted Indoor Residual Spraying (TIRS) | 2,239 | 13487 |
| Overall Study | STARTED | Routine Aedes-borne Virus (ABV) Prevention and Control | 2,222 | 13486 |
| Overall Study | COMPLETED | Targeted Indoor Residual Spraying (TIRS) | 1,835 | 10472 |
| Overall Study | COMPLETED | Routine Aedes-borne Virus (ABV) Prevention and Control | 1,718 | 13486 |
| Overall Study | NOT COMPLETED | Targeted Indoor Residual Spraying (TIRS) | 404 | 3015 |
| Overall Study | NOT COMPLETED | Routine Aedes-borne Virus (ABV) Prevention and Control | 504 | 0 |
Source ClinicalTrials.gov
Adverse events12
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Admission to emergency room due to dengue with warning signs | Infections and infestations | Targeted Indoor Residual Spraying (TIRS) | 3 | 2,239 | |
| other | Admission to emergency room due to dengue with warning signs | Infections and infestations | Routine Aedes-borne Virus (ABV) Prevention and Control | 2 | 2,222 | |
| other | Admission to emergency room due to suspected dengue with warning signs | Infections and infestations | Targeted Indoor Residual Spraying (TIRS) | 1 | 2,239 | |
| other | Admission to emergency room due to suspected dengue with warning signs | Infections and infestations | Routine Aedes-borne Virus (ABV) Prevention and Control | 2 | 2,222 | |
| other | Mild allergic reaction | General disorders | Targeted Indoor Residual Spraying (TIRS) | 1 | 2,239 | |
| other | Mild allergic reaction | General disorders | Routine Aedes-borne Virus (ABV) Prevention and Control | 0 | 2,222 | |
| other | Gastroenteritis | Gastrointestinal disorders | Targeted Indoor Residual Spraying (TIRS) | 1 | 2,239 | |
| other | Gastroenteritis | Gastrointestinal disorders | Routine Aedes-borne Virus (ABV) Prevention and Control | 0 | 2,222 | |
| serious | Leukemia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Targeted Indoor Residual Spraying (TIRS) | 0 | 2,239 | |
| serious | Leukemia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Routine Aedes-borne Virus (ABV) Prevention and Control | 1 | 2,222 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Targeted Indoor Residual Spraying (TIRS) | 1 | 2,239 |
| Total, all-cause mortality | Routine Aedes-borne Virus (ABV) Prevention and Control | 2 | 2,222 |
| Total, other adverse events | Targeted Indoor Residual Spraying (TIRS) | 6 | 2,239 |
| Total, other adverse events | Routine Aedes-borne Virus (ABV) Prevention and Control | 4 | 2,222 |
| Total, serious adverse events | Targeted Indoor Residual Spraying (TIRS) | 0 | 2,239 |
| Total, serious adverse events | Routine Aedes-borne Virus (ABV) Prevention and Control | 2 | 2,222 |
Source ClinicalTrials.gov
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U01AI148069 | Quanitifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases | VAZQUEZ PROKOPEC, GONZALO MARTIN | EMORY UNIVERSITY | NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES | 2020 to 2024 |
Source NIH RePORTER
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Targeted Indoor Residual Spraying (TIRS) vs Routine Aedes-borne Virus (ABV) Prevention and Control: deaths from any cause | Trial comparisons |
| Targeted Indoor Residual Spraying (TIRS) vs Routine Aedes-borne Virus (ABV) Prevention and Control: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04343521
GET https://conductscience.org/api/trials/v1/NCT04343521/results?page=2